Skip to content

Study · Non-randomized trial · 2026

5 results

Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.

Ni J, Lu J, Gao F, Li M, Zhang M, Du Q, Kang L, Peng D, Zhou J

Diabetes, obesity & metabolism1 Jul 2026Cited by 1 (Europe PMC)

PMID42387313 (opens in a new tab)PMCIDPMC13449076 (opens in a new tab)DOI10.1111/dom.71036 (opens in a new tab)PepBankPUB-42387313
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Asian Pacific people with type 2 diabetes on oral drugs, adding lixisenatide to insulin glargine (iGlarLixi) increased dTITR more than glargine alone (least squares mean difference 15.03%) in LixiLan-O-AP.

    In plain wordsIn Asian Pacific people with diabetes, adding lixisenatide increased time in tight glucose range compared with insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseDerived time in tight range, LixiLan-O-AP
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    LS mean difference in dTITR change from baseline versus iGlar
    15.03%
    iGlarLixi vs iGlar, LixiLan-O-AP

    Source sentences

    Summary
    From baseline to EOT, iGlarLixi provided greater increases in dTITR versus iGlar (least squares mean difference 15.03%) or Lixi (29.14%) in LixiLan-O-AP, and versus iGlar (15.93%) in LixiLan-L-CN.
    2 context sentences
    Summary · context
    A post hoc analysis was conducted of two phase 3 trials in individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin (LixiLan-L-CN).
    Summary · context
    Outcomes were evaluated from baseline to end-of-treatment (EOT; Week 24 or 30, respectively).
  2. 02HumanNon-randomized trialEfficacy outcome

    In Asian Pacific people with type 2 diabetes on basal insulin, adding lixisenatide to insulin glargine (iGlarLixi) increased dTITR more than glargine alone (least squares mean difference 15.93%) in LixiLan-L-CN.

    In plain wordsIn Asian Pacific people with diabetes, adding lixisenatide increased time in tight glucose range compared with insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseDerived time in tight range, LixiLan-L-CN
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    LS mean difference in dTITR change from baseline versus iGlar
    15.93%
    iGlarLixi vs iGlar, LixiLan-L-CN

    Source sentences

    Summary
    From baseline to EOT, iGlarLixi provided greater increases in dTITR versus iGlar (least squares mean difference 15.03%) or Lixi (29.14%) in LixiLan-O-AP, and versus iGlar (15.93%) in LixiLan-L-CN.
    2 context sentences
    Summary · context
    A post hoc analysis was conducted of two phase 3 trials in individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin (LixiLan-L-CN).
    Summary · context
    Outcomes were evaluated from baseline to end-of-treatment (EOT; Week 24 or 30, respectively).
  3. 03HumanNon-randomized trialEfficacy outcome

    In LixiLan-O-AP, 67.2% receiving iGlarLixi versus 41.1% receiving glargine achieved >50% dTITR at treatment end.

    In plain wordsIn Asian Pacific people with diabetes, more patients achieved the tight glucose range target with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAbove 50% dTITR response, LixiLan-O-AP
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    >50% dTITR rate at end of treatment
    67.2%
    iGlarLixi, LixiLan-O-AP
    >50% dTITR rate at end of treatment
    41.1%
    iGlar, LixiLan-O-AP

    Source sentences

    Summary
    At EOT, > 50% dTITR rate was 67.2%, 41.1% and 26.5% with iGlarLixi, iGlar and Lixi in LixiLan-O-AP, respectively, and 53.6% and 26.4% with iGlarLixi and iGlar in LixiLan-L-CN.
    2 context sentences
    Summary · context
    A post hoc analysis was conducted of two phase 3 trials in individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin (LixiLan-L-CN).
    Summary · context
    Outcomes were evaluated from baseline to end-of-treatment (EOT; Week 24 or 30, respectively).
  4. 04HumanNon-randomized trialEfficacy outcome

    In LixiLan-L-CN, 53.6% receiving iGlarLixi versus 26.4% receiving glargine achieved >50% dTITR at treatment end.

    In plain wordsIn Asian Pacific people with diabetes, more patients achieved the tight glucose range target with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAbove 50% dTITR response, LixiLan-L-CN
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    >50% dTITR rate at end of treatment
    53.6%
    iGlarLixi, LixiLan-L-CN
    >50% dTITR rate at end of treatment
    26.4%
    iGlar, LixiLan-L-CN

    Source sentences

    Summary
    At EOT, > 50% dTITR rate was 67.2%, 41.1% and 26.5% with iGlarLixi, iGlar and Lixi in LixiLan-O-AP, respectively, and 53.6% and 26.4% with iGlarLixi and iGlar in LixiLan-L-CN.
    2 context sentences
    Summary · context
    A post hoc analysis was conducted of two phase 3 trials in individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin (LixiLan-L-CN).
    Summary · context
    Outcomes were evaluated from baseline to end-of-treatment (EOT; Week 24 or 30, respectively).
  5. 05HumanNon-randomized trialEfficacy outcome

    In LixiLan-O-AP, 26.5% receiving lixisenatide alone achieved >50% dTITR at treatment end.

    In plain wordsIn Asian Pacific people with diabetes, 26.5% receiving lixisenatide alone reached the tight glucose-range target.

    Peptide
    Lixisenatide
    Outcome
    Not applicableAbove 50% dTITR response with lixisenatide alone
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    >50% dTITR rate at end of treatment
    26.5%
    Lixi alone, LixiLan-O-AP

    Source sentences

    Summary
    At EOT, > 50% dTITR rate was 67.2%, 41.1% and 26.5% with iGlarLixi, iGlar and Lixi in LixiLan-O-AP, respectively, and 53.6% and 26.4% with iGlarLixi and iGlar in LixiLan-L-CN.
    2 context sentences
    Summary · context
    A post hoc analysis was conducted of two phase 3 trials in individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin (LixiLan-L-CN).
    Summary · context
    Outcomes were evaluated from baseline to end-of-treatment (EOT; Week 24 or 30, respectively).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.